Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Itamar Raz et al.|New England Journal of Medicine|2018Cited by 6.3k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementF. Xavier Pi‐Sunyer, John Wilding, Arne Astrup et al.|New England Journal of Medicine|2015Cited by 2.6k
Definition and diagnostic criteria of clinical obesityFrancesco Rubino, An Pan, Naveed Sattar et al.|The Lancet Diabetes & Endocrinology|2025Cited by 1.3k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialCarel W. le Roux, Aila Rissanen, Arne Astrup et al.|The Lancet|2017Cited by 843
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trialOfri Mosenzon, Itamar Raz, Stephen D. Wiviott et al.|The Lancet Diabetes & Endocrinology|2019Cited by 673